Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells

Chimeric antigen receptor (CAR) redirected T cells are potent therapeutic options against hematological malignancies. The current dominant manufacturing approach for CAR T cells depends on retroviral transduction. With the advent of gene editing, insertion of a CD19-CAR into the T cell receptor (TCR...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Jonas Kath, Weijie Du, Alina Pruene, Tobias Braun, Bernice Thommandru, Rolf Turk, Morgan L. Sturgeon, Gavin L. Kurgan, Leila Amini, Maik Stein, Tatiana Zittel, Stefania Martini, Lennard Ostendorf, Andreas Wilhelm, Levent Akyüz, Armin Rehm, Uta E. Höpken, Axel Pruß, Annette Künkele, Ashley M. Jacobi, Hans-Dieter Volk, Michael Schmueck-Henneresse, Renata Stripecke, Petra Reinke, Dimitrios L. Wagner
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2022-06-01
Saila:Molecular Therapy: Methods & Clinical Development
Gaiak:
gene editing
CRISPR-Cas9
chimeric antigen receptor
non-viral cell manufacturing
CAR T cells
TRAC
Sarrera elektronikoa:http://www.sciencedirect.com/science/article/pii/S2329050122000511
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak